DELRAY BEACH, Fla., Oct. 2, 2026 /PRNewswire/ — According to MarketsandMarkets™, the Clinical Trial Supplies Market is projected to reach USD 8.95 billion by 2031 from USD 5.60 billion in 2026, at a CAGR of 8.9% during the forecast period.

Browse 420 market data Tables and 50 Figures spread through 450 Pages and in-depth TOC on ‘Clinical Trial Supplies Market- Global Forecast to 2031’

Clinical Trial Supplies Market Size & Forecast:

• Market Size Available for Years: 2026–2031
• 2026 Market Size: USD 5.60 billion
• 2031 Projected Market Size: USD 8.95 billion
• CAGR (2026–2031): 8.9%

Clinical Trial Supplies Market Trends & Insights:

• North America is the largest market, accounting for slightly over 41.4% of global revenue in 2025. Substantial pharmaceutical and biotechnology R&D spending, extensive clinical trial activity, and established depot and service-provider infrastructure support its leadership.
• Logistics and distribution held the largest share of the clinical trial supplies market of 27.2% in 2025. Growth is driven by multinational and decentralized trials and the increasing volume of temperature-sensitive biologics, vaccines, and advanced therapies requiring validated cold-chain transportation, customs coordination, shipment monitoring, depot-to-site delivery, and direct-to-patient distribution.
• Small molecules held the largest share, accounting for approximately 59.9% of the market in 2025. Their leadership is supported by the large number of small-molecule candidates in development, established manufacturing and regulatory pathways, broad therapeutic applications, and continued demand for oral solid-dose products requiring comparator sourcing, blinding, packaging, labeling, storage, and distribution.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=172240059

Growth is driven by the rising number of clinical trials, greater pharmaceutical and biotechnology R&D spending, and wider use of decentralized and adaptive study designs. Global and multicenter protocols also increase demand for compliant sourcing, packaging, storage, and temperature-controlled distribution.

The Logistics & Distribution Services segment is anticipated to dominate the market during the forecast period.

The services segment is sub-segmented into logistics & distribution services, storage & retention services, packaging, labeling and blinding services, manufacturing services, comparator sourcing services and other services. The logistics & distribution services segment dominated the market. The shift toward decentralized and direct-to-patient (DTP) trials has increased the need for flexible distribution models, enabling home-based delivery with real-time monitoring. As pharmaceutical and biotechnology companies expand their pipelines, demand for comparators, ancillary supplies, and investigational drugs is rising, driving growth in specialized sourcing services.

Phase III segment dominated the clinical trial supplies market in 2025

The phase segment is divided into Phase I, Phase II, Phase III, Phase IV, and Phase BA/BE. The Phase III segment dominated the clinical trial supplies market in 2025 because it plays a critical role in the drug development process and requires large-scale patient recruitment and extensive supply chain management. The Phase II segment is expected to grow at a significant CAGR during the forecast period in the clinical trial supplies market, driven by the increasing number of drug candidates advancing from preclinical to early-stage clinical trials. The rising focus on innovative therapies, including biologics, gene therapies, and targeted drugs, has led to a surge in Phase II trials, which assess the efficacy and optimal dosing of investigational treatments.

Oncology segment dominated the therapeutic area segment in 2025

The therapeutic area segment is further divided into oncology, neurology, respiratory disorders, metabolic disorders/endocrinology, cardiovascular system disorders, dermatology, gastrointestinal disorders, immunological disorders, infectious diseases, psychiatry, ophthalmology, hematology, genitourinary and women’s health, and others. The oncology segment dominated in 2025 due to factors such as an increased number of clinical trials in oncology. Oncology trials require specialized drug formulations, complex dosing regimens, and stringent regulatory compliance, increasing the need for efficient supply chain management, cold chain logistics, and sourcing of comparator drugs.

Pharmaceutical & Biotechnology Companies segment led the end-user market in 2025.

By end users, the market is segmented into pharmaceutical & biotechnology companies, CROs & CDMOs, and other end users. Pharmaceutical & biotechnology companies dominated the market in 2025 and are expected to grow at the highest CAGR during the forecast period of 2026-2031. The segment’s dominance is attributable to the rise of biologics, cell & gene therapies, and personalized medicine, which has further fueled the need for specialized logistics, cold chain storage, and regulatory-compliant distribution. The CROs and CDMOs segment is anticipated to grow at a significant CAGR in the clinical trial supplies market due to the increasing trend of outsourcing clinical trial operations by pharmaceutical and biotechnology companies.

Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=172240059

Asia Pacific is anticipated to grow at a significant CAGR during the forecast period.

The clinical trial supplies market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. In 2025, North America dominated the clinical trial supplies market due to its strong pharmaceutical and biotechnology industry, high R&D investments, and well-established clinical trial infrastructure. The United States leads the region with the highest number of clinical trials, driven by major pharmaceutical companies, CROs, and CDMOs, as well as a favorable regulatory framework established by the FDA.

Key Players

Leading players in the Clinical Trial Supplies companies include Thermo Fisher Scientific Inc. (US), Novo Holdings A/S (Denmark), Eurofins Scientific (Luxembourg), Piramal Pharma (India), Almac Group (UK), Marken (UPS) (US), PCI Pharma Services (US), Sharp Services LLC (US), Cencora, Inc. (US), Myonex (US), Clinigen Limited (UK), Inceptua Group (Luxembourg), among others.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=172240059

Clinical Trial Supplies Market – Investment & funding +Merger & Acquisition

Investment Funding Context

The clinical trial supplies market is attracting strategic investment in integrated packaging, labeling, storage, cold-chain transportation, depot networks, and digital shipment visibility. Investment is being driven by increasingly complex global trials and the specialized handling requirements of biologics, cell and gene therapies, and direct-to-patient supplies. In September 2024, PCI Pharma Services announced investments exceeding USD 365 million in US and European infrastructure supporting clinical- and commercial-scale final assembly, warehousing, and packaging of advanced drug-delivery and drug-device combination products. Logistics providers are also expanding specialized healthcare capabilities. DHL committed EUR 2 billion through 2030 to strengthen its health-logistics network, including multi-temperature infrastructure, warehouses, digital systems, and last-mile delivery capabilities. In March 2025, DHL agreed to acquire CRYOPDP, adding specialized packaging, storage, and precision-transport capabilities for pharmaceutical and biotechnology companies. In November 2025, UPS completed its USD 1.6 billion acquisition of Andlauer Healthcare Group, expanding cold-chain transportation and healthcare distribution capabilities across North America. These developments indicate sustained investment in end-to-end clinical supply platforms that manage packaging and labeling, storage, global distribution, returns, and real-time visibility while maintaining regulatory compliance and product integrity across multicountry trials.

Revenue Shift Context

The clinical trial supplies market is gradually shifting from fragmented, transaction-based purchasing of packaging, storage, and transportation services toward integrated, end-to-end supply models. Revenue opportunities are expanding beyond conventional warehousing and distribution to include demand forecasting, comparator sourcing, manufacturing, packaging and labeling, cold- and ultra-cold-chain management, direct-to-patient delivery, returns and destruction, and digital inventory visibility. Full-service providers are increasingly generating recurring revenue through multiyear global supply agreements, while specialized vendors continue to capture demand for regional depots, temperature-controlled logistics, and complex biologic and cell and gene therapy programs. The growing adoption of decentralized and hybrid trials is also shifting expenditure toward last-mile delivery, patient-kit management, home healthcare coordination, and reverse logistics. Rising protocol complexity, multinational trial footprints, and stricter product-integrity requirements are therefore increasing the revenue contribution of technology-enabled, integrated, and high-value clinical supply services relative to basic storage and transportation activities.

Mergers and Acquisitions

Mergers and acquisitions in the clinical trial supplies market during January 2025–July 2026 increasingly focused on specialized pharmaceutical logistics, temperature-controlled transportation, storage, regional distribution networks, and integrated end-to-end supply capabilities. Companies are using acquisitions to strengthen services for complex biologics, cell and gene therapies, decentralized trials, and direct-to-patient delivery. These transactions combine large global logistics networks with specialized providers offering white-glove courier services, cold-chain handling, packaging, shipment visibility, and first- and last-mile coverage, enabling sponsors to improve supply-chain resilience, geographic reach, regulatory compliance, and product integrity across multicountry clinical trials. 

CLINICAL TRIAL SUPPLIES MARKET: MERGERS AND ACQUISITIONS, JANUARY 2025–JULY 2026

Company Revenue Share Details

The top five players collectively account for an estimated 25–30% of the clinical trial supplies market, indicating a moderately consolidated but competitive market structure. The industry comprises integrated clinical supply and CDMO companies, global healthcare logistics providers, comparator-sourcing specialists, and regional packaging and depot operators. Leading participants include Thermo Fisher Scientific Inc., Novo Holdings A/S through Catalent, Piramal Group, Almac Group, Marken (UPS), PCI Pharma Services, Sharp Services LLC, Cencora, Myonex, Clinigen, Inceptua Group, and Eurofins Scientific. These companies compete based on global GMP/GDP-compliant infrastructure, manufacturing capabilities, packaging, labeling, and blinding expertise, comparator sourcing, depot coverage, temperature-controlled storage and distribution, and digital inventory visibility. Large providers differentiate themselves through integrated end-to-end platforms and extensive international networks, while specialized companies compete through regional expertise, rapid turnaround, direct-to-patient delivery, and customized packaging solutions. The coexistence of global and specialized providers creates continued scope for competition and consolidation as companies expand cold-chain capacity, geographic coverage, advanced-therapy capabilities, and technology-enabled supply-chain services.

Browse Adjacent Market: Pharmaceuticals Market Research Reports &Consulting

See More Latest Pharmaceuticals Reports:

Clinical Trial Services Market by Type (Lab, Monitoring, Contracts, Recruitment, PV, Biostatistics), Phase (I, II, III), Therapy (Oncology, Neurology, Dermatology, CVD), Modality (Biologics, Devices), Delivery Model (FSP, Hybrid) – Global forecast to 2031

Vaccines Market by Technology (Conjugate, Recombinant, Inactivated, Live Attenuated, mRNA), Type (Multivalent, Monovalent), Disease (Pneumococcal, Flu, Hepatitis, MMR, Rotavirus, RSV, HPV, Polio), ROA (IM, SC, Oral), Competition – Global Forecast to 2031

About MarketsandMarkets™  

MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

MarketsandMarkets™ SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:

Mr. Rohan Salgarkar

MarketsandMarkets™ INC.

1615 South Congress Ave.

Suite 103, Delray Beach, FL 33445

USA: +1-888-600-6441

Email: sales@marketsandmarkets.com

Visit Our Website: https://www.marketsandmarkets.com/

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/clinical-trial-supplies-market.asp

Content Source: https://www.marketsandmarkets.com/PressReleases/clinical-trial-supplies.asp

View original content to download multimedia:https://www.prnewswire.com/news-releases/clinical-trial-supplies-market-worth-8-95-billion-by-2031—exclusive-report-by-marketsandmarkets-302895758.html

SOURCE MarketsandMarkets